TG Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 9, 2022 and accepted by EDGAR at Nov 9, 2022, 16:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2022-07-01 to 2022-09-30 | $20.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-01-01 to 2022-09-30 | $95.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-07-01 to 2022-09-30 | $14.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-01-01 to 2022-09-30 | $47.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | −$35.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | −$140.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-07-01 to 2022-09-30 | $1.6m | us-gaap:InterestExpense |
| Interest expense | 9 months2022-01-01 to 2022-09-30 | $7.3m | us-gaap:InterestExpense |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | −$0.26 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | −$1.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | −$0.26 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | −$1.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 135,327,035 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 134,839,207 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | −$152.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $11.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-09-30 | $109.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $182.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $217.9m | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $36.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $117.4m | us-gaap:Liabilities |
| Long-term debt | At period end2022-09-30 | $70.0m | us-gaap:LongTermDebtNoncurrent |
Source: SEC EDGAR, the filing index for accession 0001558370-22-017180. Last ingested by Listed: Oct 24, 2026, 15:01 ET. Listed shows no prices and gives no investment advice.